Tacrolimus vs. Pimecrolimus for Vitiligo of Fingers and Lips

Site-Specific Efficacy

Both tacrolimus and pimecrolimus demonstrate comparable efficacy for vitiligo affecting the lips, with 50-100% repigmentation rates, according to the British Journal of Dermatology guidelines 1, 2
The British Journal of Dermatology recommends both agents as alternatives to potent topical steroids for facial areas, given their superior safety profile 1, 2
Tacrolimus specifically failed to produce repigmentation for lesions on the hands in children, indicating this anatomical site is resistant to calcineurin inhibitor therapy, as noted by the British Journal of Dermatology 1, 2

Both agents offer superior safety compared to potent topical corticosteroids, particularly for facial application where steroids risk atrophy, telangiectasia, and ocular complications, according to the British Journal of Dermatology 1, 2
The British Journal of Dermatology specifically recommends these agents in children due to their better short-term safety profile versus highly potent steroids 2, 3

For lip vitiligo, the British Journal of Dermatology suggests initiating tacrolimus 0.1% ointment twice daily, with pimecrolimus 1% cream twice daily as an alternative if tacrolimus is unavailable 1, 2
For finger vitiligo, the British Journal of Dermatology advises against using calcineurin inhibitors as monotherapy due to documented poor efficacy, and considers narrowband UVB phototherapy instead 1, 2

The guideline evidence from the British Journal of Dermatology provides Level 2+ evidence, acknowledging the studies are small and explicitly calling for head-to-head trials 1, 2, 4

The American Academy of Dermatology recommends that topical tacrolimus for vitiligo does not require Complete Metabolic Panel (CMP) monitoring or any routine laboratory testing, as systemic absorption is negligible and the medication is applied locally to skin lesions 5, 6
The critical point is that topical tacrolimus 0.1% ointment used for vitiligo has an entirely different safety profile than oral tacrolimus used in transplant patients, with oral tacrolimus requiring extensive monitoring including renal function, blood glucose, blood pressure, and drug levels due to risks of nephrotoxicity, diabetes, and hypertension 5

No laboratory monitoring is recommended in vitiligo guidelines for topical tacrolimus, according to the British Journal of Dermatology 6
The American Academy of Dermatology notes that oral tacrolimus for psoriasis or transplant requires extensive monitoring, but this does not apply to topical tacrolimus for vitiligo 5